MURRAY HILL, N.J.–(BUSINESS WIRE)–C. R. Bard, Inc. (NYSE: BCR) today announced that it has acquired Lutonix, Inc. for a purchase price of approximately $225 million paid at closing Read More…

Lead Program Includes Novel Investigational Compound for Prevention/Treatment of Skin Scarring

NEW YORK & SAN DIEGO–Pfizer Inc. (NYSE: PFE) and Excaliard Pharmaceuticals, Inc. announced today that they have entered into a definitive agreement under which Pfizer will acquire Excaliard, a privately owned biopharmaceutical company focused on developing novel drugs for the treatment of skin fibrosis, more commonly referred to as skin scarring. Read More…

Stent Patients with High Platelet Reactivity Had Twice the Rate of Cardiovascular Events

SAN DIEGO, CA  – Accumetrics, Inc., developer of the VerifyNow® System, the first rapid and easy-to-use point-of-care system for measuring platelet reactivity to multiple antiplatelet agents, today announced that results from a patient-level meta-analysis of more than 3,000 stent patients have been published in the Journal of the American College of Cardiology1. Read More…

Observed Clinical Activity Suggests OTO-104 Provides Clinically Meaningful Reduction in Vertigo Frequency and Improvement in Tinnitus

San Diego, CA – Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced that researchers presented positive new data from a Phase 1b study of the company’s lead product candidate, OTO-104, in patients with Ménière’s disease. Read More…